INTERACT vs Pre-IND Meeting: Which FDA Meeting to Request
Compare FDA INTERACT and Pre-IND meetings, including timing, evidence thresholds, and how to choose the right early FDA engagement for your program.
Read
Compare FDA INTERACT and Pre-IND meetings, including timing, evidence thresholds, and how to choose the right early FDA engagement for your program.
Read
Understand the key differences between FDA Fast Track and Breakthrough Therapy designations, from eligibility criteria to development benefits.
Read
Learn how FDA's decentralized review structure shapes orphan drug designation strategy, and why OOPD requires a medically plausible basis for designation.
Read
Learn how to obtain EMA orphan drug designation, how it differs from FDA ODD, and how Only Orphans Cote helps biotechs win EU rare disease approvals.
Read
For those developing drugs for rare diseases the FDA offers four programs to expedite the process and reach patients faster. Contact us for more info!
Read
February 3, 2026 was a significant day for the rare pediatric disease community. The Consolidated Appropriations Act of 2026 was signed into law, reauthorizing the Rare Pediatric Disease
Read
Comprehensive guide to FDA tropical disease priority review vouchers (PRVs) worth $160M+. Learn eligibility requirements, qualifying diseases, and how to structure your development program for PRV success.
Read
Learn which cancers qualify for FDA orphan designation based on U.S. prevalence, how globally common cancers may still be eligible, and what benefits sponsors unlock for rare cancer drug development.
Read
Understand the core requirements of IND-enabling studies that support FDA clearance for first-in-human trials and how strategic planning accelerates approval.
Read
Learn why FDA issues deficiency letters for Orphan Drug Designation applications. Understand the most common pitfalls in medical rationale and prevalence justification.
Read